Tabelecleucel for EBV+ PTLD following allogeneic HCT or SOT in a multicenter expanded access protocol.
Nikiforow S, Whangbo JS, Reshef R, Tsai DE, Bunin NJ, Abu-Arja RF, Mahadeo KM, Weng WK, Van Besien K, Loeb D, Nasta SD, Nemecek ER, Zhao W, Sun Y, Galderisi FC, Wahlstrom J, Mehta A, Gamelin LI Dr, Dinavahi R, Prockop SE.
Nikiforow S, et al. Among authors: nasta sd.
Blood Adv. 2024 Apr 16:bloodadvances.2023011626. doi: 10.1182/bloodadvances.2023011626. Online ahead of print.
Blood Adv. 2024.
PMID: 38625984